Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses
Authors:
- Kris BaertKBKris Baert
- Siska CroubelsSiska Croubels
- Gunther van LoonGunther van Loon
- An MaesAMAn Maes
- Rene TavernierRTRene Tavernier
- Piet DeprezPDPiet Deprez
- Patrick De BackerPBPatrick De Backer
- 1 March 2006
- journal article
- clinical trial
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 67 (3) , 448-454
Abstract
Objective—To determine the clinical effects and pharmacokinetics of amiodarone after single doses of 5 mg/kg administered orally or intravenously. Animals—6 healthy adult horses. Procedure—In a cross over study, clinical signs and electrocardiographic variables were monitored and plasma and urine samples were collected. A liquid chromatography–mass spectrometry method was used to determine the percentage of protein binding and to measure plasma and urine concentrations of amiodarone and the active metabolite desethylamiodarone. Results—No adverse clinical signs were observed. After IV administration, median terminal elimination half-lives of amiodarone and desethylamiodarone were 51.1 and 75.3 hours, respectively. Clearance was 0.35 L/kg•h, and the apparent volume of distribution for amiodarone was 31.1 L/kg. The peak plasma desethylamiodarone concentration of 0.08 μg/mL was attained 2.7 hours after IV administration. Neither parent drug nor metabolite was detected in urine, and protein binding of amiodarone was 96%. After oral administration of amiodarone, absorption of amiodarone was slow and variable; bioavailability ranged from 6.0% to 33.7%. The peak plasma amiodarone concentration of 0.14 μg/mL was attained 7.0 hours after oral administration and the peak plasma desethylamiodarone concentration of 0.03 μg/mL was attained 8.0 hours after administration. Median elimination half-lives of amiodarone and desethylamiodarone were 24.1 and 58.6 hours, respectively. Conclusion and Clinical Relevance—Results indicate that the pharmacokinetic distribution of amiodarone is multicompartmental. This information is useful for determining treatment regimens for horses with arrythmias. Amiodarone has low bioavailability after oral administration, does not undergo renal excretion, and is highly protein-bound in horses.Keywords
This publication has 35 references indexed in Scilit:
- Pharmacological Cardioversion of Atrial FibrillationDrugs, 2004
- Disposition of Intravenous Amiodarone in Subjects with Normal and Impaired Renal FunctionThe Journal of Clinical Pharmacology, 1996
- AmiodaroneDrugs, 1992
- Factors Affecting Prognosis and Conversion in Equine Atrial FibrillationJournal of Veterinary Internal Medicine, 1988
- A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient.Circulation, 1984
- Clinical Pharmacokinetics of AmiodaroneClinical Pharmacokinetics, 1984
- Amiodarone pharmacokineticsAmerican Heart Journal, 1983
- Amiodarone: Historical development and pharmacologic profileAmerican Heart Journal, 1983
- Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.Circulation, 1983
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978